Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Hoffman

Showing results (451-460 of 470) with videos related to

Pageof 47
Sort By:
Arthritis & Rheumatology (Hoboken, N.J.)|October 11, 2016
Gene Expression and Pharmacodynamic Changes in 1,760 Systemic Lupus Erythematosus Patients From Two Phase III Trials of BAFF Blockade With TabalumabRobert W Hoffman, Joan T Merrill, Marta M E Alarcón-Riquelme, et al.
Annals of Internal Medicine|October 1, 1994
Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trialD W Maher, G J Lieschke, M Green, et al.
Journal of Sports Science & Medicine|May 19, 2015
Effects of time-release caffeine containing supplement on metabolic rate, glycerol concentration and performanceAdam M Gonzalez, Jay R Hoffman, Adam J Wells, et al.
Lancet (London, England)|July 26, 2018
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trialDaniel J Wallace, Richard A Furie, Yoshiya Tanaka, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2007
A phase I biodistribution and pharmacokinetic trial of humanized monoclonal antibody Hu3s193 in patients with advanced epithelial cancers that express the Lewis-Y antigenAndrew M Scott, Niall Tebbutt, Fook-Thean Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2012
Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patientsPaul Sabbatini, Takemasa Tsuji, Luis Ferran, et al.
Annals of Emergency Medicine|October 3, 2006
ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injuryDavid W Wright, Arthur L Kellermann, Vicki S Hertzberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2005
Phase I trial of 131I-huA33 in patients with advanced colorectal carcinomaGeoffrey Chong, Fook Thean Lee, Wendie Hopkins, et al.
Gynecologic Oncology|June 1, 2015
A phase II trial with anti-Lewis-Y monoclonal antibody (hu3S193) for the treatment of platinum resistant/refractory ovarian, fallopian tube and primary peritoneal carcinomaOren Smaletz, Maria D P E Diz, Claudio C do Carmo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 10, 2003
A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancerAndrew M Scott, Greg Wiseman, Sydney Welt, et al.
Pageof 47

Showing results (451-460 of 470) with videos related to

Sort By:
Pageof 47
Arthritis & Rheumatology (Hoboken, N.J.)|October 11, 2016
Gene Expression and Pharmacodynamic Changes in 1,760 Systemic Lupus Erythematosus Patients From Two Phase III Trials of BAFF Blockade With TabalumabRobert W Hoffman, Joan T Merrill, Marta M E Alarcón-Riquelme, et al.
Annals of Internal Medicine|October 1, 1994
Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trialD W Maher, G J Lieschke, M Green, et al.
Journal of Sports Science & Medicine|May 19, 2015
Effects of time-release caffeine containing supplement on metabolic rate, glycerol concentration and performanceAdam M Gonzalez, Jay R Hoffman, Adam J Wells, et al.
Lancet (London, England)|July 26, 2018
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trialDaniel J Wallace, Richard A Furie, Yoshiya Tanaka, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2007
A phase I biodistribution and pharmacokinetic trial of humanized monoclonal antibody Hu3s193 in patients with advanced epithelial cancers that express the Lewis-Y antigenAndrew M Scott, Niall Tebbutt, Fook-Thean Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2012
Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patientsPaul Sabbatini, Takemasa Tsuji, Luis Ferran, et al.
Annals of Emergency Medicine|October 3, 2006
ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injuryDavid W Wright, Arthur L Kellermann, Vicki S Hertzberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2005
Phase I trial of 131I-huA33 in patients with advanced colorectal carcinomaGeoffrey Chong, Fook Thean Lee, Wendie Hopkins, et al.
Gynecologic Oncology|June 1, 2015
A phase II trial with anti-Lewis-Y monoclonal antibody (hu3S193) for the treatment of platinum resistant/refractory ovarian, fallopian tube and primary peritoneal carcinomaOren Smaletz, Maria D P E Diz, Claudio C do Carmo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 10, 2003
A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancerAndrew M Scott, Greg Wiseman, Sydney Welt, et al.
Pageof 47